Indicators for monitoring the 2016 United Nations Political Declaration on Ending AIDS
UNAIDS supports countries to collect information on their national HIV responses through the Global AIDS Monitoring (GAM) framework—an annual collection of 72 indicators on the response to HIV in a country.... These data form part of the data set used to report back to the General Assembly.
Different from the HIV epidemiological estimates that countries produce for data on the state of the epidemic in a country—that is, data for making estimates on the number of people living with HIV, AIDS-related deaths, etc.—GAM collects information on HIV programmes, including the number of people living with HIV who know their HIV status and people on HIV treatment, and on stigma and discrimination. A full list of the indicators is given in the GAM guidelines.
more
UNAIDS 2018, Guidance
Indicators for monitoring the
2016 Political Declaration on Ending AIDS
Enhancing Men’s Role in HIV Prevention
A Meand to enhancing HIV prevention in key populations. This document has been developed out of the increasing need to set up standards and procedures to prevent and respond to violence against key populations.
Refugees1 with disabilities have specific needs and face particular forms of discrimination. As highlighted in the Executive Committee Conclusion No. 110 (LXI)–2010, it is important for UNHCR to ensure that the rights of persons with disabilities who are of concern to the Office are met without di...scrimination. This places an onus on offices to develop a thorough
understanding of the circumstances of persons with disabilities under their care. This note provides staff with guidance on a range of issues to consider in meeting these responsibilities.
more
This study provides information about vulnerabilities within the targeted population and contributes to reflection within UNHCR on how to interpret their multisectorial Home Visit assessments. By exploring relationships between vulnerability indicators and other data collected, the report outlines k...ey trends and relationships. The report details predefined VAF indicators and then provides an in-depth descriptive analysis for each sector
more
Manufacturers:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) ir...respective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more